WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WuXi Biologics has announced its partnership with Amicus Therapeutics in celebrating the European Commission's approval of Pombiliti™ (cipaglucosidase alfa) for adults with late-onset Pompe disease. This therapy, a combined treatment with miglustat, is a significant milestone achieved through WuXi's advanced manufacturing capabilities since the therapy's inception in 2012. The approval is based on clinical data from the Phase 3 PROPEL trial, which included a diverse patient population. WuXi Biologics continues to support commercialization through its global sourcing strategy, reinforcing its position as a leader in biologics development.
- European Commission approved Pombiliti™ for late-onset Pompe disease, enhancing market position for Amicus and WuXi.
- Approval based on Phase 3 PROPEL trial data, indicating strong clinical efficacy.
- WuXi's involvement in the therapy's development since 2012 highlights their manufacturing capabilities.
- None.
Pombiliti™ was started at
"The joint efforts between Amicus and
About AT-GAA
AT-GAA is an investigational two-component therapy that consists of cipaglucosidase alfa, a bis-M6P-enriched rhGAA which facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that's designed to minimize loss of enzyme activity in the blood. In clinical studies, AT-GAA was associated with demonstrated improvements in both musculoskeletal and respiratory measures.
About Pompe Disease
Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly fatal infantile form with significant impacts to heart function, to a more slowly progressive, late-onset form primarily affecting skeletal muscle and progressive respiratory involvement. Late-onset Pompe disease can be severe and debilitating, including progressive muscle weakness throughout the body, particularly the skeletal muscles and muscles controlling breathing, that worsens over time.
About
With over 12,000 skilled employees in
For more information about
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-congratulates-amicus-therapeutics-on-european-commission-approval-for-pombiliti-in-patients-with-late-onset-pompe-disease-301783244.html
SOURCE
FAQ
What is the significance of the European Commission approval for Pombiliti?
When did WuXi Biologics start working on Pombiliti?
What is the relationship between WuXi Biologics and Amicus Therapeutics regarding Pombiliti?
What is the Phase 3 PROPEL trial related to Pombiliti?